Investigating Descartes-08 for myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental therapy called Descartes-08, made from your own immune cells, to see if it can improve muscle weakness in people with generalized myasthenia gravis. The therapy is designed to target and reduce harmful antibodies that cause the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have generalized myasthenia gravis with moderate to severe symptoms (MGFA grades 2-4).
- Your daily symptoms score (MG-ADL) is 6 or higher.
- You have a positive blood test for acetylcholine receptor antibodies (AChR) within the last 10 years.
- If you take steroids, your daily dose is 40 mg or less of prednisone (or equivalent), and has been steady for at least 8 weeks.
- You have not been diagnosed with generalized MG within the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
This trial tests a new treatment called Descartes-08 for people with dermatomyositis or antisynthetase syndrome whose disease hasn't responded well to standard therapies. It aims to see if this treatment can help control muscle and skin symptoms.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This study follows people with suspected or confirmed myasthenia gravis (a condition that causes muscle weakness that gets worse with use). It uses several specialized nerve and antibody tests to make a more precise diagnosis and tracks you over time to see how well these methods work.
Hear when a new Myasthaenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.